Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of Tecarfarin in Healthy Chinese Volunteers
NCT04627116Phase 1Unknown
- Sponsor
- Lee's Pharmaceutical Holdings Limited
- Start
- Apr 2020
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of tecarfarin in thromboembolism (4 arms), sponsored by Lee's Pharmaceutical Holdings Limited. Primary endpoint: Safety and tolerability of Tecarfarin at 14 days. Status: unknown.
02
Drugs
tecarfarin
03
Conditions
thromboembolism
Beyond the preview
Go deeper on NCT04627116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04627116.